MX2024010565A - Procedimiento de fabricacion de un antagonista cristalino del receptor edg-2. - Google Patents
Procedimiento de fabricacion de un antagonista cristalino del receptor edg-2.Info
- Publication number
- MX2024010565A MX2024010565A MX2024010565A MX2024010565A MX2024010565A MX 2024010565 A MX2024010565 A MX 2024010565A MX 2024010565 A MX2024010565 A MX 2024010565A MX 2024010565 A MX2024010565 A MX 2024010565A MX 2024010565 A MX2024010565 A MX 2024010565A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- edg
- crystalline
- receptor antagonist
- methylphenethoxy
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- SOJDTNUCCXWTMG-UHFFFAOYSA-N 2-[[4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzoyl]amino]-1,3-dihydroindene-2-carboxylic acid Chemical compound COC1=CC=C(C(=O)NC2(CC3=CC=CC=C3C2)C(O)=O)C=C1OCCC1=CC=CC(C)=C1 SOJDTNUCCXWTMG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315898P | 2022-03-02 | 2022-03-02 | |
| PCT/IB2023/000120 WO2023166346A1 (en) | 2022-03-02 | 2023-03-01 | Process of making a crystalline edg-2 receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010565A true MX2024010565A (es) | 2024-09-06 |
Family
ID=86054291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010565A MX2024010565A (es) | 2022-03-02 | 2023-03-01 | Procedimiento de fabricacion de un antagonista cristalino del receptor edg-2. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12391640B2 (enExample) |
| EP (1) | EP4486719A1 (enExample) |
| JP (1) | JP2025507801A (enExample) |
| AU (1) | AU2023228095A1 (enExample) |
| CA (1) | CA3251849A1 (enExample) |
| MX (1) | MX2024010565A (enExample) |
| TW (1) | TW202346256A (enExample) |
| WO (1) | WO2023166346A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12391640B2 (en) | 2022-03-02 | 2025-08-19 | Horizon Therapeutics Ireland Dac | Process of making a crystalline EDG-2 receptor antagonist |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571506A (en) | 1989-08-14 | 1996-11-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
| WO1992020350A1 (en) | 1991-05-20 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
| US6225352B1 (en) | 1996-08-14 | 2001-05-01 | Warner-Lambert Company | Low molecular weight dendritic compounds as pharmaceutical agents |
| US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6969529B2 (en) | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
| AU5300000A (en) | 1999-06-01 | 2000-12-18 | Elan Pharma International Limited | Small-scale mill and method thereof |
| US20040026546A1 (en) | 2000-04-26 | 2004-02-12 | Czekai David A | Apparatus for sanitary wet milling |
| JPWO2001094309A1 (ja) | 2000-06-02 | 2004-02-05 | 塩野義製薬株式会社 | Ｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物 |
| CA2415900A1 (en) | 2000-07-14 | 2002-01-31 | The Uab Research Foundation | Uses for nad synthetase inhibitors |
| US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US6656971B2 (en) | 2001-01-25 | 2003-12-02 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
| JP4223390B2 (ja) | 2001-06-05 | 2009-02-12 | エラン・ファルマ・インターナショナル・リミテッド | 材料をフライス削りするシステムおよび方法 |
| WO2003006628A2 (en) | 2001-07-13 | 2003-01-23 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| ATE487470T1 (de) | 2002-09-11 | 2010-11-15 | Elan Pharma Int Ltd | Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| EP1626742A1 (en) | 2003-05-22 | 2006-02-22 | Elan Pharma International Limited | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
| JPWO2005012221A1 (ja) | 2003-08-04 | 2006-09-14 | 小野薬品工業株式会社 | ジフェニルエーテル化合物、その製造方法および用途 |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| EP1836182A2 (en) | 2004-11-18 | 2007-09-26 | The Institutes for Pharmaceutical Discovery, LLC | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| US20090124654A1 (en) | 2005-03-01 | 2009-05-14 | Mjalli Adnan M M | Aryl and Heteroaryl Compounds, Compositions, Methods of Use |
| PL2003132T3 (pl) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| PT2303270T (pt) | 2008-05-05 | 2017-08-25 | Sanofi Sa | Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| EP3167875A1 (en) | 2009-05-27 | 2017-05-17 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| CN112184094B (zh) | 2019-07-03 | 2024-08-20 | 北京京东振世信息技术有限公司 | 一种地址信息采集方法和装置 |
| KR20220161476A (ko) | 2020-04-02 | 2022-12-06 | 호라이즌 테라퓨틱스 아일랜드 디에이씨 | 전신 경화증의 치료 방법 |
| TW202227390A (zh) | 2020-08-31 | 2022-07-16 | 法商賽諾菲公司 | 結晶型edg-2受體拮抗劑及製造方法 |
| US12391640B2 (en) | 2022-03-02 | 2025-08-19 | Horizon Therapeutics Ireland Dac | Process of making a crystalline EDG-2 receptor antagonist |
-
2023
- 2023-03-01 US US18/176,862 patent/US12391640B2/en active Active
- 2023-03-01 JP JP2024551569A patent/JP2025507801A/ja active Pending
- 2023-03-01 WO PCT/IB2023/000120 patent/WO2023166346A1/en not_active Ceased
- 2023-03-01 EP EP23718334.8A patent/EP4486719A1/en active Pending
- 2023-03-01 CA CA3251849A patent/CA3251849A1/en active Pending
- 2023-03-01 MX MX2024010565A patent/MX2024010565A/es unknown
- 2023-03-01 AU AU2023228095A patent/AU2023228095A1/en active Pending
- 2023-03-02 TW TW112107594A patent/TW202346256A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025507801A (ja) | 2025-03-21 |
| CA3251849A1 (en) | 2023-09-07 |
| WO2023166346A1 (en) | 2023-09-07 |
| EP4486719A1 (en) | 2025-01-08 |
| US12391640B2 (en) | 2025-08-19 |
| US20230295073A1 (en) | 2023-09-21 |
| TW202346256A (zh) | 2023-12-01 |
| AU2023228095A1 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010565A (es) | Procedimiento de fabricacion de un antagonista cristalino del receptor edg-2. | |
| PH12022552321A1 (en) | Process, compositions, and crystalline forms of substituted pyridinonepyridinyl compounds | |
| UA100964C2 (ru) | Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила | |
| NO329181B1 (no) | Symmetrisk og usymmetrisk substituerte difenylureaforbindelser og farmasoytiske preparater som omfatter disse | |
| EP1451163A4 (en) | 3-AMIDO-1,2-BENZOXOXAZOLE DERIVATIVES, METHOD OF MANUFACTURE AND ITS USE | |
| CA3241670A1 (en) | Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor | |
| MX2024007907A (es) | Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo. | |
| MX2025006444A (es) | Proceso para la sintesis de moduladores de tetrahidrofurano sustituidos de los canales de sodio | |
| CA3242815A1 (en) | Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof | |
| JOP20240290A1 (ar) | أملاح أوبيسترابيب وعمليات تصنيعها والمركبات الوسيطة منها | |
| EP4624474A4 (en) | Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor | |
| WO2023278843A3 (en) | Solid forms of osanetant | |
| MX2021002311A (es) | Metodo para producir un compuesto tetraciclico. | |
| EA202192731A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА | |
| EP4349991A4 (en) | Strain for producing highly concentrated l-glutamic acid, and l-glutamic acid production method using same | |
| EP4613270A3 (en) | Crystalline form of acetylcholinesterase inhibitor and preparation method therefor and application thereof | |
| ZA202409657B (en) | Method for producing sulfone derivative using haloacetic acid | |
| MX2024013485A (es) | Formas salinas y cristalinas de un inhibidor del receptor del factor de crecimiento epidermico | |
| EA202192389A1 (ru) | Новый способ получения филготиниба и его промежуточных соединений | |
| MX2021010549A (es) | Proceso para preparar [4-(hidroxicarbamoil) fenil]carbamato de {6-[(dietilamino)metil]naftalen-2-il}metilo de alta pureza. | |
| MX2024011415A (es) | Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos. | |
| WO2021240547A3 (en) | Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forms thereof | |
| MX2021014246A (es) | Procedimientos y productos intermedios para preparar un inhibidor de btk. | |
| RU2012126058A (ru) | Способ получения 2,2-диброммалонамида | |
| JP2013542258A5 (enExample) |